Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • jeff_texas_nola jeff_texas_nola Mar 7, 2013 8:50 AM Flag

    This has positive implications for ICT-107....Phase 1/2 DCVax-Direct clinical trial will not be blinded

    This has positive implications for ICT-107: News has come from Northwest Biotherapeutics (NWBO) on its DCVax® personalized immune therapies for solid tumor cancers. The information is an announcement that Phase 1/2 DCVax-Direct clinical trial for all inoperable solid tumor cancers, which is planned to begin within approximately the next sixty days, will not be blinded. This means that the results will be seen as the trial proceeds. Knowing that an efficacy endpoint is tumor shrinkage or elimination), this trial is expected to yield meaningful ongoing results by the second half of 2013......DCVAX is also available for compassionate use in Europe and will probably gain that status in the US shortly

    This innovative clinical trial is approved by the FDA for all types of solid tumor cancers (i.e., cancers in any tissues of the body), and is configured to provide rapid results....... DCVAX is also available for compassionate use in Europe.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Jeff, the trial doesn't have a control group so there is no need for them to blind the results. However, I would tell you that we are completely blinded. The trial has been going on for years and we still don't know where they are with enrollment other than between 0 and 312 patients. Before this update, we were supposed to hear results, not completed enrollment, but results in June. Before that, it was one date, before that it was another date. So despite the fact that you have heard that the results will not be blinded, I can tell you that I am completely blind in terms of where they are in the progress of their trial.

      • 1 Reply to discoduck33
      • Based on the science IMUC should be better due to the targeting of the DCs for the CSCs.....They should be able to combine there 107 and 121, as well and it the DC CSC approach could apply to 80% of Solid Mass Tumors......I started investing in IMUC and IMUC CALLs after three highly respected MD PHDs told me that ICT-107 was revolutionary..... This was about 8 months ago..... I have been following the progress for the last 2 years..... A couple comments: It would seems that orphan drug approval and compassionate use would be awarded with a 6 plus month OS advantage along with a P3 Study. The P3 may not be a randomized/placebo, if the data demonstrates 12 plus month increase in OS PFS. Also this Particular DC-CSC Therapy could....ie all the ICTs could apply to 80% of cancers..... the non-clinical OS for Standard of care for GBM is still around 11-13 months.....I understand that the SOC OS will likely be 18 to 19 for this study.....I do not see any reason to use RT and TMZ in future care....apply the ICTs as quickly after surgery as possible to avoid massive up regulation of growth hormones during the post surgery healing process....the ICTs DC-CSC therapy will also likely to be combined with each other and other immuno-stimulants and other adjuncts, which would further increase PSF and OS Less

        Sentiment: Strong Buy

    • This design will not pass muster on this side of the pond. The EU can give limited approval after PII (CE Mark)
      but, again, the trail design is not optimal for this. At any rate, the biggest problem for NWBO is a debt that is almost 20% larger that their market cap! They recently did a reverse split to try to gain investors but, as is usually the case w/a R/S, it lowered the market cap even more. If this co. survives, it will probably be at the expense of the current investors - again.

 
IMUC
0.2148-0.0033(-1.51%)Feb 9 4:00 PMEST